MBRX
NASDAQ
$2.46
Moleculin Biotech Inc (MBRX)
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant viruses and tumors in the United States. The company is headquartered in Houston, Texas.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $21 (+753.66%)
Market Cap
$15M
P/B Ratio
0.95
Beta (5Y)
1.43
Price Chart
Valuation
Market Cap$15M
P/B0.95
Profitability
EBITDA-$27M
EPS-$25.11
Growth & Risk
EPS 5Y CAGR-27.22%
FCF 5Y CAGR+6.86%
Beta (5Y)1.43
Sharpe Ratio-0.91